Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial
about
sameAs
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromesDrug-eluting stents versus bare metal stents for angina or acute coronary syndromesEverolimus-eluting stents in interventional cardiologyAcute reductions in mechanical wall strain precede the formation of intimal hyperplasia in a murine model of arterial occlusive disease.Neointimal hyperplasia associated with synthetic hemodialysis grafts.Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study.Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centreBenefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.Smooth muscle specific overexpression of p22phox potentiates carotid artery wall thickening in response to injury.First human trial of KW39 slotted-tube stents: for percutaneous coronary interventionCoronary stent thrombosis: current insights into new drug-eluting stent designsC-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic targetDrug-eluting stent safety: findings from preclinical studies.A review of current devices and a look at new technology: drug-eluting stents.Drug-eluting stent coatings.Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.Benefits of and safety concerns associated with drug-eluting coronary stents.Recent developments in drug-eluting stents.Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.How safe and how good are drug-eluting stents?Drug-eluting stents and balloons in peripheral arterial disease: evidence so far.New treatments for infrapopliteal disease: devices, techniques, and outcomes so far.Perioperative antiplatelet management in patients with coronary artery stenting.Systematic review and meta-analysis of balloon angioplasty versus primary stenting in the infrapopliteal disease.Drug-eluting versus bare-metal coronary stents: where are we now?Choosing the right coronary stent in the modern era.Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.Multiple Stent Fractures After Everolimus-Eluting Stent Implantation Causing Acute Myocardial Infarction: A Case Report.Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement.Clinical outcome of titanium-nitride-oxide-coated cobalt-chromium stents in patients with de novo coronary lesions: 12-month results of the OPTIMAX first-in-man study.Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning.Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).Stent outcomes for infrapopliteal arterial occlusive disease.Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: results of long-term follow-up.Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent.Are drug-eluting stents safe?: Definitely! Or probably... possibly? Or maybe not yet....Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry.Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.Disruptive technological advances in vascular access for dialysis: an overview.Clinical, humanistic, and economic outcomes between drug-eluting stent (DES) and bare metal stent (BMS): 18-month follow-up study.
P2860
Q24186681-4FAC9847-5C32-43BB-B1BF-6DD521359269Q24235466-79B18EFC-EEB7-4D19-9782-7E1704E863D1Q24630321-AEA6B17A-AA91-4423-AFF6-A3A056F325F6Q30399953-75308507-F657-477C-B829-D09D64BE2C8DQ30492883-6295B3F1-FF30-4427-9F9C-1FBFA6353CE9Q31021002-D7133D61-7B6B-4BC7-9803-1263FD20A88EQ34024602-A2FE970F-28C2-4549-834F-4DD645E3447CQ34646022-03ADC1BC-0BB5-4569-B8CA-E660BCE57589Q35471157-10DB4894-C4CE-4031-BA32-EE09C5B1E8BEQ35594750-DDFDE8B3-CD03-455E-A6EC-FC69151E6FB7Q36514842-5629DFFE-CD91-498E-B0F2-A81B075AE8D8Q36708991-79E4D46B-8FA1-428E-A4D1-FD5123D10416Q37329149-1EA06AD3-0BF7-4D74-9E3D-24F34B069678Q37357342-52898F90-27C1-4684-BF65-193865B3DF61Q37668357-AA70E1F2-74B3-4EEB-94A3-40268769D07BQ37685137-90F03696-A963-428A-A643-4EF5011D20AFQ37707419-FA1D038D-398D-4BBF-8E7B-236A97690D9FQ37833534-FB5CF0E4-F22E-4157-B5B8-54F11042B5AEQ37858604-A51AB530-F763-406A-80DC-28A8654253A0Q37859760-BF285495-671C-47A4-B8CD-ABB2C3AB1ECBQ37874693-ACED3F80-584F-4800-A3B4-1163831715F6Q38010314-C4760CCC-B63A-4417-936D-95F307611272Q38012080-E520F3E0-6DD6-4888-A59A-48D5E51376E4Q38161317-4EC7CD8C-1642-4D03-8EC7-AF1355449DC7Q38162864-D8E4D3E1-3D68-4AEE-93F5-FE92A0336064Q38194095-A948C96D-4EEF-44FD-B1D8-6E7A0AA68A3AQ38388101-1E69829F-E35E-486D-8626-A690CA48800FQ38446241-8961A1BF-D9C8-41F6-AB69-26CC53F9A080Q39505785-FA7F924A-0115-43BA-8AB8-032B2A458AEAQ41450796-40035478-F37A-4E40-AC73-89CF573BD154Q41634009-6E81F91A-C112-4E21-88BD-B8F96B753F6CQ43477596-CE64AC9B-935A-44B0-972F-76D6699FE08DQ44338039-63CE355D-E21A-4C6C-8828-42DF5A09428BQ44763980-13E05503-980E-4C82-B970-CCB9451F3FC6Q44941164-C59BAF0E-008A-4AE8-A9C7-E8C9A5930BE3Q45924411-DC7D833B-83A3-4AB2-A252-69C90AE068E1Q46942290-19C75003-2DE7-46D6-B661-2CD772420FF7Q47750245-F98E22EA-C446-4465-A9EA-B04EDEE3FBE1Q48213898-FC769208-2117-4EA6-BEBC-2B893B383E01Q51116480-DB0BB13A-BCA6-4911-AA46-4C195AC53430
P2860
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@ast
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@en
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@nl
type
label
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@ast
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@en
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@nl
altLabel
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents
@en
prefLabel
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@ast
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@en
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@nl
P2093
P50
P1476
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents
@en
Long-term clinical outcomes wi ...... ear results of the RAVEL trial
@en
P2093
David Snead
Donald E Cutlip
Donald E. Cutlip
Eduardo Sousa
Gerrit-Anne Van Es
Hans-Peter Stoll
Laura Mauri
Paul Barragan
P304
P356
10.1016/J.JACC.2007.06.029
P407
P577
2007-10-01T00:00:00Z
2007-10-02T00:00:00Z